WO2015073967A1 - Nouveaux métabolites de composés de vanoxérine pour le traitement de maladies dopaminergiques - Google Patents

Nouveaux métabolites de composés de vanoxérine pour le traitement de maladies dopaminergiques Download PDF

Info

Publication number
WO2015073967A1
WO2015073967A1 PCT/US2014/065943 US2014065943W WO2015073967A1 WO 2015073967 A1 WO2015073967 A1 WO 2015073967A1 US 2014065943 W US2014065943 W US 2014065943W WO 2015073967 A1 WO2015073967 A1 WO 2015073967A1
Authority
WO
WIPO (PCT)
Prior art keywords
vanoxerine
treatment
hydroxide
piperazine compound
compound
Prior art date
Application number
PCT/US2014/065943
Other languages
English (en)
Inventor
Arthur M. Brown
Original Assignee
Brown Arthur M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown Arthur M filed Critical Brown Arthur M
Publication of WO2015073967A1 publication Critical patent/WO2015073967A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des modes de réalisation de la présente invention concernent des compositions comprenant de nouveaux composés de pipérazine appropriés pour être administrés à un mammifère pour le traitement de maladies dopaminergiques, et des méthodes d'administration de celles-ci.
PCT/US2014/065943 2013-11-15 2014-11-17 Nouveaux métabolites de composés de vanoxérine pour le traitement de maladies dopaminergiques WO2015073967A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904724P 2013-11-15 2013-11-15
US61/904,724 2013-11-15

Publications (1)

Publication Number Publication Date
WO2015073967A1 true WO2015073967A1 (fr) 2015-05-21

Family

ID=53058137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/065943 WO2015073967A1 (fr) 2013-11-15 2014-11-17 Nouveaux métabolites de composés de vanoxérine pour le traitement de maladies dopaminergiques

Country Status (1)

Country Link
WO (1) WO2015073967A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022031407A1 (fr) * 2020-08-03 2022-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands gpr101 pour le traitement de troubles liés à l'hormone de croissance
ES2920173A1 (es) * 2021-01-28 2022-08-01 Consejo Superior Investigacion Antimicrobianos frente a patogenos del genero streptococcus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0099148A1 (fr) * 1982-06-29 1984-01-25 Gist-Brocades N.V. Dérivés de pipérazine, leurs procédés de préparation en compositions pharmaceutiques les contenant
WO1998018769A1 (fr) * 1996-10-31 1998-05-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives a liberation prolongee d'analogues hydroxyles de 1-[2[bis(aryl)methoxy]ethyl]-piperazines et -homopiperazines substituees et leur utilisation comme antagonistes non competitifs du recaptage de la dopamine
US6835371B1 (en) * 1997-09-12 2004-12-28 David R. Elmaleh Diagnostic and therapeutic piperazine and piperidine compounds and process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0099148A1 (fr) * 1982-06-29 1984-01-25 Gist-Brocades N.V. Dérivés de pipérazine, leurs procédés de préparation en compositions pharmaceutiques les contenant
WO1998018769A1 (fr) * 1996-10-31 1998-05-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives a liberation prolongee d'analogues hydroxyles de 1-[2[bis(aryl)methoxy]ethyl]-piperazines et -homopiperazines substituees et leur utilisation comme antagonistes non competitifs du recaptage de la dopamine
US6835371B1 (en) * 1997-09-12 2004-12-28 David R. Elmaleh Diagnostic and therapeutic piperazine and piperidine compounds and process

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022031407A1 (fr) * 2020-08-03 2022-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands gpr101 pour le traitement de troubles liés à l'hormone de croissance
ES2920173A1 (es) * 2021-01-28 2022-08-01 Consejo Superior Investigacion Antimicrobianos frente a patogenos del genero streptococcus
WO2022162265A1 (fr) * 2021-01-28 2022-08-04 Consejo Superior De Investigaciones Científicas (Csic) Antimicrobiens dirigés contre des pathogènes du genre streptocoque

Similar Documents

Publication Publication Date Title
AU2008240259C1 (en) Tetrahydrobiopterin compositions and methods of measuring
AU2006295440B2 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
EP2961383B1 (fr) Suspension pour administration par voie orale comprenant du tolvaptan amorphe
US20100273825A1 (en) Solid pharmaceutical composition containing solifenacin amorphous form
US20170224666A9 (en) Immediate-release tablet formulations of a thrombin receptor antagonist
AU2016224503A1 (en) Solid preparation
EP1938804A1 (fr) Préparation pharmaceutique comprenant un antagoniste de neurokinine
EP2826477B1 (fr) Composition solide de sel d'amino carboxylate
JP2019529491A (ja) 毛髪の成長を刺激するためのアルファ−ケトブチレート、アルファ−ケトグルタレート、および２−ヒドロキシブチレート
JP2747303B2 (ja) ペルゴリド化合物の安定化
US20120028992A1 (en) Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
EP2833871B1 (fr) Compositions pharmaceutiques orales stables à libération immédiate et contenant du prasugrel
EP1092431B1 (fr) Compositions contenant du lasofoxifène
WO2015073967A1 (fr) Nouveaux métabolites de composés de vanoxérine pour le traitement de maladies dopaminergiques
WO2019149159A1 (fr) Composition comprenant un dérivé d'oxadiazole, son procédé de préparation et son utilisation
US10722469B2 (en) Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
US20110064806A1 (en) Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
US20160304477A1 (en) Novel metabolites of vanoxerine compounds, pharmaceutical compositions containing the same and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals
CA2951768C (fr) Desmopressine stabilisee
AU2013201986B2 (en) Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
WO2014059346A1 (fr) Procédés de traitement d'états impliquant la dopamine par l'administration de composés de pipérazine
KR20240064728A (ko) 세피아프테린의 제약 조성물
WO2015119938A1 (fr) Compositions pharmaceutiques pour mettre fin à des épisodes aigus d'arythmie cardiaque, pour restaurer le rythme sinusal, pour prévenir la récurrence de l'arythmie cardiaque et/ou pour maintenir un rythme sinusal normal chez des mammifères
US20160303114A1 (en) Pharmaceutical compositions containing vanoxerine and p450 inhibitors and methods of terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythym in mammals through administration of said compositions
US20120059013A1 (en) Method of treating early morning akinesia in subjects having parkinson's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14861237

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14861237

Country of ref document: EP

Kind code of ref document: A1